Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Other Non Operating Income (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Other Non Operating Income for 15 consecutive years, with -$1000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 50.0% to -$1000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5000.0 through Dec 2025, up 112.82% year-over-year, with the annual reading at $5000.0 for FY2025, 112.82% up from the prior year.
  • Other Non Operating Income hit -$1000.0 in Q4 2025 for Cardiff Oncology, roughly flat from -$1000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $270000.0 in Q4 2021 to a low of -$253000.0 in Q2 2022.
  • Historically, Other Non Operating Income has averaged $1368.4 across 5 years, with a median of -$1000.0 in 2025.
  • Biggest five-year swings in Other Non Operating Income: soared 10250.0% in 2021 and later plummeted 1300.0% in 2022.
  • Year by year, Other Non Operating Income stood at $270000.0 in 2021, then crashed by 116.67% to -$45000.0 in 2022, then soared by 71.11% to -$13000.0 in 2023, then soared by 84.62% to -$2000.0 in 2024, then skyrocketed by 50.0% to -$1000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for CRDF at -$1000.0 in Q4 2025, -$1000.0 in Q2 2025, and $7000.0 in Q1 2025.